US5137919A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
Assignee: Otsuka America Pharmaceutical Inc
•
Filing: 1990-12-31
•
Granted: 1992-08-11
•
Expires: 2010-12-31
Abstract
Abstract The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors), and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.
Inventors
- 👤 Yasuyuki Igarashi
- 👤 Mahammad N. Ahmad
- 👤 Hirofumi Okoshi
- 👤 Sen-itiroh Hakomori
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 11:28
CPC Classifications
C; C07; C07C; C07C215/00; C07C215/02; C07C215/40
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
1 words
N,N,N-trimethylsphingosine.
Claim 2
Dependent Claim
1 words
N,N,N-trimethylsphingosine.
Claim 3
Dependent Claim
6 words
A pharmaceutically acceptable salt of N,N,N-trimethylsphingosine.
Claim 4
Dependent Claim
6 words
A pharmaceutically acceptable salt of N,N,N-trimethylsphingosine.
Claim 5
Dependent Claim
25 words
A medicament comprising: (a) a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier, diluent or excipient.
Claim 6
Dependent Claim
25 words
A medicament comprising: (a) a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier, diluent or excipient.
Claim 7
Dependent Claim
18 words
A composition comprising: (a) a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine; and (b) a carrier, diluent or buffer.
Claim 8
Dependent Claim
18 words
A composition comprising: (a) a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine; and (b) a carrier, diluent or buffer.
Claim 9
Independent Claim
17 words
A method for inhibiting cell proliferation comprising contacting cells with a cell growth inhibitory amount of N,N,N-trimethylsphingosine.
Claim 10
Independent Claim
17 words
A method for inhibiting cell proliferation comprising contacting cells with a cell growth inhibitory amount of N,N,N-trimethylsphingosine.
Claim 11
Dependent Claim
13 words
The method of claim 5, wherein said contacting step is performed in vitro.
Claim 12
Dependent Claim
13 words
The method of claim 5, wherein said contacting step is performed in vivo.
Claim 13
Dependent Claim
11 words
The method of claim 5, wherein said cells are cancer cells.
Claim 14
Dependent Claim
13 words
The method of claim 5, wherein said cells are of the immune system.
Claim 15
Dependent Claim
56 words
An N,N,N-trimethylsphingosine made by the process comprising the steps of: (a) dissolving (4E)-N,N-dimethyl-D-erythro-sphingosine in an anhydrous organic buffer to produce a solution; (b) dissolving in said solution of step (a) freshly distilled iodomethane to produce a mixture; (c) incubating said mixture of step (b) to produce a N,N,N-trimethylsphingosine product; and (d) separating said N,N,N-trimethylsphingosine produced therefrom.
Claim 16
Dependent Claim
56 words
An N,N,N-trimethylsphingosine made by the process comprising the steps of: (a) dissolving (4E)-N,N-dimethyl-D-erythro-sphingosine in an anhydrous organic buffer to produce a solution; (b) dissolving in said solution of step (a) freshly distilled iodomethane to produce a mixture; (c) incubating said mixture of step (b) to produce a N,N,N-trimethylsphingosine product; and (d) separating said N,N,N-trimethylsphingosine produced therefrom.
Claim 17
Dependent Claim
12 words
The N,N,N-trimethylsphingosine of claim 10, wherein said organic buffer is anhydrous chloroform.
Claim 18
Dependent Claim
13 words
The N,N,N-trimethylsphingosine of claim 10, wherein said iodomethane is present in 25-100% excess.
Claim 19
Dependent Claim
14 words
The N,N,N-trimethylsphingosine of claim 10, wherein said mixture of step (c) is incubated overnight.
Claim 20
Dependent Claim
39 words
The N,N,N-trimethylsphingosine of claim 10 wherein said process further comprises the step of: (e) stirring said product of step (d) with neutralized anion exchange resin to produce halogen derivatized N,N,N-trimethylsphingosine; and (f) separating said halogen derivatized N,N,N-trimethylsphingosine produced therefrom.
Claim 21
Independent Claim
16 words
A method of inhibiting platelet aggregation comprising exposing platelets to an aggregation inhibiting amount of N,N,N-trimethylsphingosine.
Claim 22
Independent Claim
16 words
A method of inhibiting platelet aggregation comprising exposing platelets to an aggregation inhibiting amount of N,N,N-trimethylsphingosine.
Claim 23
Dependent Claim
15 words
The method of claim 15 wherein said platelet aggregation is induced by a cancer cell.
Claim 24
Dependent Claim
25 words
A medicament comprising: (a) a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier, diluent or excipient.
Claim 25
Dependent Claim
25 words
A medicament comprising: (a) a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier, diluent or excipient.
Claim 26
Dependent Claim
18 words
A composition comprising: (a) a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine; and (b) a carrier, diluent or buffer.
Claim 27
Dependent Claim
18 words
A composition comprising: (a) a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine; and (b) a carrier, diluent or buffer.
Claim 28
Dependent Claim
25 words
A therapeutic method comprising administering to a host in need of treatment a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine or a pharmaceutically acceptable salt thereof.
Claim 29
Dependent Claim
25 words
A therapeutic method comprising administering to a host in need of treatment a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine or a pharmaceutically acceptable salt thereof.
Claim 30
Dependent Claim
25 words
A therapeutic method comprising administering to a host in need of treatment a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine or a pharmaceutically acceptable salt thereof.
Claim 31
Dependent Claim
25 words
A therapeutic method comprising administering to a host in need of treatment a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-08-11 | 1996-02-10 | 1996-08-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-08-11 | 2000-02-10 | 2000-08-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-08-11 | 2004-02-10 | 2004-08-11 | $7700.00 | Window Closed / Lapsed |